Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

@article{Socinski2001PhaseIT,
  title={Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.},
  author={Mark A. Socinski and Alan B. Sandler and Langdon L. Miller and Paula K Locker and C K Hanover and Gary L. Elfring and Valerie K. Israel and Nicoletta Pirotta and Ronald B. Natale},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 4},
  pages={1078-87}
}
PURPOSE To determine the maximum-tolerated dose, toxicities, and dose suitable for phase II/III trials of irinotecan (CPT-11) combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with stage IIIB/IV NSCLC were enrolled to this multicenter, phase I study. The initial regimen was… CONTINUE READING